Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | TP53 | P04637 | 7/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | PKLR | P30613 | 3/20 | 0.66 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.66 |
| ▸ | TUBB | P07437 | 1/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.66 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.66 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.66 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022521 | 1.00 | MAPT (0.74) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL1967979 | 0.90 | TUBB4A (0.64) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL2977993 | 0.90 | MAPT (0.77) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL29981081 | 0.90 | MAPT (0.77) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL14022520 | 0.90 | GAA (0.67) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL29980270 | 0.88 | MAPT (0.74) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL997306 | 0.85 | TP53 (0.87) | MAPTTP53PKMPKLRGAA | |
| SCHEMBL26908188 | 0.83 | MAPT (0.69) | MAPTTP53PKMPKLRTUBB4A | |
| SCHEMBL998959 | 0.83 | GAA (0.88) | MAPTTP53PKMTUBB4ATUBB | |
| SCHEMBL27101731 | 0.82 | MAPT (0.66) | MAPTTP53PKMPKLRTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | claimed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | claimed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | claimed |
| CN-115286629-B | Method for preparing medicine intermediate 3-anilioimidazole [1,2-a ] pyridine derivative through catalysis | 安徽工业大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115286629-A | Method for preparing medical intermediate 3-phenylamino imidazole [1,2-a ] pyridine derivative through catalysis | 安徽工业大学 | 2022-11-04 | — | — | CN | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | MAPT 1239/4885TP53 4070/4885PKM 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.